EXPRESSION OF CD47 AND CALR IN MYELOFIBROSIS
Research type
Research Study
Full title
EXPRESSION OF CD47 AND CALR IN MYELOFIBROSIS: POTENTIAL NEW THERAPEUTICAL TARGET AND IMPACT OF MAGROLIMAB
IRAS ID
302706
Contact name
Ciro Rinaldi
Contact email
Sponsor organisation
University of Lincoln
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Myelofibrosis is a cancer of the bone morrow and part of a group of conditions called myeloproliferative neoplasms. It causes abnormalities in blood counts like anaemia and neutropenia, systemic symptoms such as weight loss and fatigue and enlarged spleen. It can progress into acute leukaemia and it is currently incurable. The use of a monoclonal antibody against the “anti-eat me signal CD47”, Magrolimab, could represent a new strategy to enhance the effect of standard chemotherapy by increasing the expression of the “eat-me” signal CALR. This could result in improving efficacy of standard therapy and to achieve significant improvement in survival.
To confirm participants will not be given the study drug and this is an in-vitro study using blood and bone marrow samples.REC name
Yorkshire & The Humber - South Yorkshire Research Ethics Committee
REC reference
21/YH/0218
Date of REC Opinion
16 Sep 2021
REC opinion
Favourable Opinion